Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Boehringer Ingelheim Kg

Sanofi-aventis

Sanofi

Hubert Heuer

Heiner Glombik

Wendelin Frick

Werner Kramer

Hans-Ludwig Schaefer

Gerhard Jaehne

Stefanie Flohr

Andreas Lindenschmidt

Stefan Petry

Gerhard Zoller

Norbert Tennagels

Harm Brummerhop

Stefan Theis

Karl-Heinz Baringhaus

Alfons Enhsen

Franz Birke

Gunter Müller

Oliver Plettenburg

Werner Stransky

Gunter Muller

Hans-Ludwig Schäfer

Karl-Heinz Weber

Wolf-Dietrich Bechtel

Werner Krame

Kurt Schromm

Siegfried Stengelin

Dieter Kadereit

Ernst-Otto Renth

Ralf Anderskewitz

Armin Fugner

Ulrike Kufner-Muhl

Christopher John Meade

Günter Müller

Eric Galia

Albrecht Harreus

Martin Bickel

Karl Schoenafinger

Gerhard Walther

Andreas W Herling

Reinhard Kirsch

Matthias Urmann

Gojko Muacevic

Thomas Klabunde

Jorge Casals-Stenzel

Guenter Mueller

Armin Bauer

Karl H Weber

Hans-Ludwig Sch&auml;fer

Manfred Seidel

Ulrike Kuefner-Muehl

Susanne Kilp

Wendeline Frick

Harm Brummerhof

The present invention relates to 5-oxoisoxazole derivatives of the formula I, the pharmaceutically usable salts thereof and the use thereof as medicinal substances. 

5-oxoisoxazoles as inhibitors of lipases and phospholipases

The invention relates to azole derivatives of the general formula I as defined in the present application as well as to their uses in treatment of conditions that would benefit from their inhibitory effect on hormone sensitive lipase, HSL, an allosteric enzyme in adipocytes which is inhibited by insulin and is responsible for the breakdown of fats in fat cells and thus for transferring fat constituents into the blood stream. Inhibition of this enzyme is therefore equivalent to an insulin-like effect of the compounds of the invention.

Azole derivatives in the form of lipase and phospholipase inhibitors

The invention relates to the use of substituted pyranone acid derivatives and of their physiologically acceptable salts for producing medicaments for treating the metabolic syndrome.

Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome

The invention relates to diacyl indazole derivatives of general formulae (I) or (II) and to the pharmaceutically acceptable salts thereof: Wherein X, R1 and R2 are as defined herein. The invention also relates to the use of these compounds to treat diabetes mellitus, dyslipidemia and atherosclerotic disorders.

Diacyl indazole derivatives as lipase and phospholipase inhibitors

The present invention comprises methods for reducing plasma lipids, plasma free fatty acids (FFA), plasma glycerol and triglycerides in a mammal through the administration of certain substituted cyclopropane acid derivatives of Formula 1: wherein R1-R6 are defined herein and pharmaceutical compositions comprising them.

Use of substituted cyclopropane acid derivatives for producing drugs for use in the treatment of metabolic syndrome

This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and use thereof.

1,4-benzothiepin-1, 1-dioxide derivatives with improved properties method for producing the same, drugs containing said compounds and the use thereof

This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof.

1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof

The invention relates to benzothiazol-2-one derivatives of general formula (I) with the meanings indicated in the description, the pharmaceutically usable salts thereof, and the use thereof as medicinal substances. 

Benzothiazol-2-one derivatives as lipase and phospholipase inhibitors

The present invention relates to indazole derivatives of the general formulae I or II having the meanings indicated in the description, to the pharmaceutically useful salts thereof and the use thereof as drugs. 

Indazole derivatives as inhibitors of hormone sensitive lipase

This invention relates to Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof.

1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof

This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof.

1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof

The present invention provides compounds which have an inhibitory effect on hormone-sensitive lipase or endothelial lipase. The compounds of the invention are azolopyridin-2-one derivatives of the general formula I wherein the substituents are as defined herein. The compounds of formula I wherein R2 is hydrogen are distinguished by favorable effects on disorders of lipid metabolism. They beneficially influence the HDL to LDL ratio and increase in particular the HDL level and are suitable for the prevention and treatment of dyslipidemias and metabolic syndrome and their diverse sequelae such as atherosclerosis, coronary heart disease, heart failure, obesity and diabetes. The compounds of formula I wherein R1 and R2 together form a ring system are distinguished by favorable effects on metabolic disorders. They beneficially influence lipid and sugar metabolism; in particular they lower the triglyceride level and are suitable for the prevention and treatment of type II diabetes and arteriosclerosis and the diverse sequelae thereof.

Azolopyridin-2-one derivatives as lipase and phospholipase inhibitors

The invention relates to substituted fluoroglycoside derivatives of pyrazoles of formula (I) as further defined in the specification, to the physiologically compatible salts thereof, to a method for their production, and to their use as antidiabetics. 

Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof

The invention relates to diacyl indazole derivatives of general formulae (I) or (II) and to the pharmaceutically acceptable salts thereof:  Wherein X, R1 and R2 are as defined herein. The invention also relates to the use of these compounds to treat diabetes mellitus, dyslipidemia and atherosclerotic disorders.

The invention relates to the compound of the formula 1 and to its physiologically acceptable salts. The compound is suitable, for example, as a hypolipidemic.

Diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use

Growing community of inventors

Schwabenheim, Germany

Hubert Heuer